Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men

View ORCID ProfileFlávio Adsuara Cadegiani, John McCoy, View ORCID ProfileCarlos Gustavo Wambier, View ORCID ProfileAndy Goren
doi: https://doi.org/10.1101/2020.11.16.20232512
Flávio Adsuara Cadegiani
1Department of Clinical Endocrinology, Federal University of São Paulo Medical School, Sao Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Flávio Adsuara Cadegiani
John McCoy
2Applied Biology, Inc. Irvine, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: johnm@appliedbiology.com
Carlos Gustavo Wambier
3Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlos Gustavo Wambier
Andy Goren
2Applied Biology, Inc. Irvine, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andy Goren
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background SARS-CoV-2 entry into type II pneumocytes is depended on the TMPRSS2 proteolytic enzyme. The only known promoter of TMPRSS2 in humans is an androgen response element. As such, androgen sensitivity may be a risk factor for COVID-19. Previously, we have reported a retrospective cohort analysis demonstrating the protective effect of 5-alpha-reductase inhibitors (5ARis) in COVID-19. Men using 5ARis were less likely to be admitted to the ICU than men not taking 5ARis. Additionally, men using 5ARis had drastically reduced frequency of symptoms compared to men not using 5ARis in an outpatient setting. Here we aim to determine if 5ARis will be a beneficial treatment if given after SARS-CoV-2 infection.

Methods A double-blinded, randomized, prospective, investigational study of dutasteride for the treatment of COVID-19 (NCT04446429). Subjects confirmed positive for SARS-CoV-2 were treated in an outpatient setting. Endpoints for the study were remission times for a predetermined set of symptoms: fever or feeling feverish, cough, shortness of breath, sore throat, body pain or muscle pain/ache, fatigue, headache, nasal congestion, nasal discharge (runny nose), nausea or vomiting, diarrhea, loss of appetite, and loss of taste or smell (Ageusia or Anosmia).

Results A total of 130 SARS-CoV-2 positive men were included in the study, 64 subjects in the dutasteride arm and 66 subjects in the placebo-controlled group. The differences in the average remission times for fatigue and anosmia or ageusia was statistically different between the groups (5.8 versus 10.1 days for fatigue and 7.3 versus 13.4 days for anosmia or ageusia, in dutasteride and placebo groups, respectively), however, the total remission time was significantly reduced for the men given dutasteride; 9.0 days versus 15.6 days in the placebo group (p < 0.001). Excluding loss of taste and smell the average total remission time was 7.3 days in the dutasteride group versus 11.7 in the placebo arm (p < 0.001).

Conclusion The total remission time for men using 5ARis was significantly reduced compared to men not taking 5ARis.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04446429

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study is registered (clinicaltrial.gov) and conducted with the consent and approval of the Brazilian National Ethics Committee (CEP/CONEP) (CAAE: 34110420.2.0000.0008).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding sources: None

  • Conflicts of Interest: None declared.

  • IRB approval status: The study was approved by an ethics committee and registered with clinicaltrials.gov (NCT04446429).

Data Availability

The supplement data is available under request to FAC (f.cadegiani@gmail.com).

  • Abbreviations

    5ARi
    5-alpha reductase inhibitors
    TMPRSS2
    Transmembrane protease, serine 2
    AGA
    Androgenetic alopecia
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
    Back to top
    PreviousNext
    Posted November 18, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
    Flávio Adsuara Cadegiani, John McCoy, Carlos Gustavo Wambier, Andy Goren
    medRxiv 2020.11.16.20232512; doi: https://doi.org/10.1101/2020.11.16.20232512
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
    Flávio Adsuara Cadegiani, John McCoy, Carlos Gustavo Wambier, Andy Goren
    medRxiv 2020.11.16.20232512; doi: https://doi.org/10.1101/2020.11.16.20232512

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (179)
    • Allergy and Immunology (434)
    • Anesthesia (99)
    • Cardiovascular Medicine (948)
    • Dentistry and Oral Medicine (178)
    • Dermatology (110)
    • Emergency Medicine (260)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
    • Epidemiology (8987)
    • Forensic Medicine (4)
    • Gastroenterology (420)
    • Genetic and Genomic Medicine (1959)
    • Geriatric Medicine (190)
    • Health Economics (402)
    • Health Informatics (1329)
    • Health Policy (660)
    • Health Systems and Quality Improvement (519)
    • Hematology (212)
    • HIV/AIDS (420)
    • Infectious Diseases (except HIV/AIDS) (10809)
    • Intensive Care and Critical Care Medicine (575)
    • Medical Education (200)
    • Medical Ethics (54)
    • Nephrology (222)
    • Neurology (1830)
    • Nursing (110)
    • Nutrition (274)
    • Obstetrics and Gynecology (353)
    • Occupational and Environmental Health (470)
    • Oncology (999)
    • Ophthalmology (298)
    • Orthopedics (111)
    • Otolaryngology (182)
    • Pain Medicine (126)
    • Palliative Medicine (44)
    • Pathology (265)
    • Pediatrics (580)
    • Pharmacology and Therapeutics (276)
    • Primary Care Research (234)
    • Psychiatry and Clinical Psychology (1903)
    • Public and Global Health (4123)
    • Radiology and Imaging (676)
    • Rehabilitation Medicine and Physical Therapy (368)
    • Respiratory Medicine (549)
    • Rheumatology (225)
    • Sexual and Reproductive Health (191)
    • Sports Medicine (177)
    • Surgery (207)
    • Toxicology (39)
    • Transplantation (109)
    • Urology (81)